Meplazumab  (Synonyms: HcHAb18)

Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a K_d of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Basigin/CD147

Meplazumab significantly inhibits SARS-CoV-2 infection in vitro, with measurable cytopathic effect blocking (IC₅₀ = 24.86 μg/mL), viral titer suppression (IC₅₀ = 15.16 μg/mL)^[1].
Meplazumab (72 h) significantly inhibits SARS-CoV-2 pseudovirus infection of activated human CD4⁺ and CD8⁺ T cells^[2].
Meplazumab (100 μg/mL; 2 h) internalizes into NCI-H460 non-small cell lung cancer cells at 37 °C and traffics to lysosomes, while remaining primarily on the cell surface at 4 °C^[3].
Meplazumab (10 μg/mL; 2 h) does not disrupt microtubule organization, centrosome separation, or chromosome alignment in mitotic NCI-H460 non-small cell lung cancer cells^[3].
Meplazumab (72 h) does not exert significant antiproliferative activity in NCI-H460, NCI-H226, NCI-H520, A549, A549 CD147-knock down, or MRC-5 cells^[3].
Meplazumab binds to purified CD147 antigen with high affinity, with an equilibrium dissociation constant of 0.47 nM^[3].
Meplazumab (conjugated with DM1) induces G2/M phase cell cycle arrest and exerts antiproliferative activity in non-small cell lung cancer cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Meplazumab (32 mg/kg; i.v.; twice weekly; 4 weeks) achieves 48.87% tumor volume inhibition and 46.28% tumor weight inhibition in A549 NSCLC xenograft nude mice with no significant impact on body weight^[3].
Meplazumab (10 mg/kg; i.v.; twice weekly; 4 weeks) achieves 47.39% tumor volume inhibition and 48.80% tumor weight inhibition in NCI-H226 NSCLC xenograft nude mice with stable body weight^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

682  [NCBI]

P35613

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.86 kDa

Liquid

Colorless to light yellow

[Meplazumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bian H, et al. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial. Signal Transduct Target Ther. 2021;6(1):194. Published 2021 May 17.  [Content Brief]

  [2]. Wang K, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020;5(1):283. Published 2020 Dec 4.  [Content Brief]

  [3]. Huhe M, et al. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer. Biochem Biophys Res Commun. 2019;513(4):1083-1091.  [Content Brief]